CD4 and cardiovascular disorder: In our study, polypharmacy was associated with age (mean: 37.17 ± 11.84 vs. 48.00 ± 12.71 years, P < 0.001), nadir CD4 [median: 323 (10–928) vs. 255 (4–918) cell/mm3, P = 0.03], duration of ART [median: 27 (3–320) vs. 46 (6–236) months, P = 0.009], intensive treatment and integrase inhibitor-based treatment (P < 0.001), and diseases of the cardiovascular system (CVS) (P < 0.001) and the central nervous system (CNS) (P < 0.001).